Insmed (INSM) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Viatris (VTRS) has outperformed Insmed (INSM) over the past year, gaining 74.9% versus a loss of 37.3%. Over five years, INSM leads with a +284.1% price change compared with +29.9% for VTRS. Insmed is the larger company by market cap ($21.94 billion vs $20.03 billion), about 1.1 times the size.
On valuation, Viatris trades at a lower forward P/E (6.5x vs 127.6x for Insmed). Viatris pays a dividend yielding 2.75%, while Insmed does not currently pay one. Viatris converts more of its revenue into profit, with a net margin of -24.6% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | VTRS |
|---|---|---|
| Share price | $100.48 | $17.44 |
| Market cap | $21.94B | $20.03B |
| 1-day change | -1.24% | -0.29% |
| YTD return | -41.54% | +40.08% |
| 1-year return | -37.32% | +74.92% |
| 5-year return | +284.07% | +29.94% |
| Forward P/E | 127.61 | 6.52 |
| EPS (TTM) | $-4.10 | $-0.36 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $606.42M | $14.30B |
| Revenue growth (YoY) | +66.73% | -2.98% |
| Net income (latest FY) | $-1.28B | $-3.51B |
| Gross margin | 79.73% | 35.06% |
| Operating margin | -205.59% | -18.62% |
| Net margin | -210.54% | -24.58% |
| 52-week high | $212.75 | $18.43 |
| 52-week low | $90.39 | $9.69 |
| Distance from 52-week high | -52.77% | -5.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +96.80% | +12.96% |
| Average volume | 2.57M | 9.18M |
| Shares outstanding | 218.38M | 1.15B |
| Employees | 1,664 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed INSM by 112.2 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.75% vs 0.00%).
- Viatris is more profitable, keeping -24.6 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs -2.98%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
INSM vs VTRS FAQ
Which is bigger, Insmed or Viatris?
Insmed (INSM) is larger, with a market capitalization of $21.94B compared with $20.03B for Viatris (VTRS).
Which stock has performed better over the past year, INSM or VTRS?
VTRS returned +74.92% over the past 12 months, compared with -37.32% for INSM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Insmed or Viatris?
Viatris pays a dividend yielding 2.75%, while Insmed does not currently pay a regular dividend.
Are Insmed and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.